Search Results
Your search for ,NOt matches 22378 pages
Showing 17651 - 17700Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma
Most relapses following treatment for diffuse large B-cell lymphoma are detected by abnormalities on physical exam, lab tests, and symptoms—not by routine imaging, according to a study presented at the ASCO Annual Meeting.1 In fact, in a prospective study assessing post-treatment outcomes of...
Potent Activity Shown for First-in-class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia
Heavily pretreated patients with chronic lymphocytic leukemia (CLL) responded robustly to the first-in-class small-molecule inhibitor idelalisib (formerly GS1101), in a phase I dose-finding study reported in a press briefing prior to the 2013 ASCO Annual Meeting.1 Idelalisib, a specific inhibitor...
Expert Point of View: Roy S. Herbst, MD, PhD
This study should be placed in the context of treating to cure, said Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and Chief of Medical Oncology at Yale University School of Medicine, New Haven, Connecticut. “If we can further increase the cure rate in stage III non–small cell lung cancer...
Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies
Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...
'Less Is More' with Regard to Adjuvant Radiation in Stage III Non–Small Cell Lung Cancer
Standard-dose conformal radiotherapy (60 Gy) is more effective and safer than high-dose radiotherapy (74 Gy) in patients with locally advanced stage III non–small cell lung cancer (NSCLC) undergoing chemotherapy, according to results of the phase III randomized, controlled Radiation Therapy...
One Cancer Center's Approach to Death with Dignity
In November 2008, the Washington State legislature passed the Washington Death with Dignity Act allowing patients with a terminal diagnosis and less than 6 months to live to request and self-administer lethal medication. After considerable internal debate, our cancer center elected to develop a...
Caring for the Whole Patient Both during Active Treatment and at End of Life
Despite studies showing that a majority of patients prefer to die at home rather than in an institutional setting,1 in many parts of the country, over 30% die in nursing homes and over 50% die in hospitals, according to Ira Byock, MD, Director of Palliative Medicine, Dartmouth-Hitchcock Medical...
For Renowned Researcher, Seeing Basic Science Turn into Promising Therapies Is the 'Holy Grail' of Oncology
“From bench to bedside” is a phrase that captures the essence of modern oncology: Researchers at the bench seek to solve the biologic puzzles of cancer that can translate into the development of therapeutics delivered at the bedside. Owen N. Witte, MD, has spent most of his career as a basic bench...
Innovative Leader in Oncology Is Committed to Tackling the Most Critical Issues in Managed Care
“I’m a Nebraskan,” said Lee N. Newcomer, MD, MHA, a leader in the oncology community who is well known for his innovative efforts to align physician payment and quality of care in ways that will best configure to the rapidly changing health-care environment. Speaking in the flat vowels and neutral...
The Power of Listening: From Candy Striper to the Front Lines of the Early AIDS Pandemic
Alexandra Levine, MD, MACP, the Chief Medical Officer of City of Hope National Medical Center, has traveled to 74 countries, seeking out adventures in some of the world’s most far-flung regions. Her illustrious oncology journey has also been an adventure, from the front lines of the AIDS pandemic...
Expert Genitourinary Oncologist's Drive Led Her from Baghdad to the United States
Born in Baghdad, Iraq, renowned prostate and bladder cancer specialist Maha H. Hussain, MD, FACP, Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center, remembers that she always wanted to become a doctor. She had strong role models in three uncles who were...
UICC President Balances Innovation and Pragmatism to Reduce the Global Burden of Cancer
Mary K. Gospodarowicz, MD, FRCPC, is determined to help reduce the worldwide burden of cancer, a problem of epic proportions. Her approach is simple: adopt what works and reject what doesn’t. Much progress in the fight against cancer can be made without waiting for the next paradigm-changing...
Pioneering Oncologist's Research on Cisplatin Revolutionized Testicular Cancer Treatment
Lawrence H. Einhorn, MD, grew up in Dayton, Ohio, in a time and place that he describes as pleasant and community-oriented. Throughout his distinguished career, Dr. Einhorn has maintained strong roots in the Midwest. “After finishing high school, I did my undergrad at Indiana University and went to ...
After a Distinguished Career, Trailblazing Swiss Oncologist Remains Devoted to Addressing the Global Cancer Challenge
Switzerland, a landlocked country with a population about that of New York City, has four geographic regions, each with its own official language. Internationally regarded lymphoma and breast cancer expert, Franco Cavalli, MD, FRCP, was born and raised in Locarno, a town in the Italian region of...
Distinguished Researcher Changed the Face of Hematologic Malignancies
Clara D. Bloomfield, MD, grew up in a steadfastly academic environment that spurned typical children’s entertainment such as comic books or television. Born in New York City during World War II, she moved to Washington, DC, with her family while her father, an expert on labor and industrial...
The Road to ASCO Presidency, Paved by Education and Persistence
ASCO President Clifford A. Hudis, MD, grew up in northeast Philadelphia in the 1960s, a robust period in U.S. history dominated by American industry and ingenuity. His early memories are of a hard-working blue-collar neighborhood of identical row and semidetached twin houses and of a time of...
Emil 'Tom' Frei III, MD 1924–2013
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
FDA Clears Multicenter Trial of Treatment for Hair Loss Related to Chemotherapy
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
Strength of Patient-Oncologist Alliance Linked to Willingness to Adhere to Treatment in Young Adults
Among young adults with advanced cancer, developing a strong alliance with their oncologist was associated with greater perceived social support, a greater willingness to adhere to treatment, and greater adherence to oral medication, according to results of a study published in the Journal of...
DCIS Score Quantifies Risk of Recurrence after Excision
The ductal carcinoma in situ (DCIS) Score, a multigene expression assay, quantifies the risk of local recurrence and invasive local recurrence for women with DCIS treated with surgical excision, researchers reported in the Journal of the National Cancer Institute. “The DCIS Score can aid clinical...
No Added Benefit from Radiotherapy after Lumpectomy/Tamoxifen in Older Women
Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9343 “confirms and extends the earlier report that in women age ≥ 70 years with clinical stage I, [estrogen receptor (ER)]-positive breast cancer treated with lumpectomy followed by tamoxifen, irradiation adds no significant benefit in...
Chemotherapy-induced Peripheral Neuropathy Results in Dose Limiting and Less Chemotherapy Overall
Chemotherapy-induced peripheral neuropathy events resulted in limiting the dosing of chemotherapy in a significant proportion of women with nonmetastatic breast cancer being treated with paclitaxel, and those who had their dose reduced or discontinued received significantly less cumulative drug,...
Liver-first Approach to Colorectal Cancer with Synchronous Hepatic Metastases
“The liver-first approach for patients with colorectal cancer with synchronous liver metastases is possible but is associated with a wide range of survival outcomes, despite protocol similarities between studies,” according to a review of four cohort studies identified by a literature search. “All...
SIDEBAR: Expect Questions about Preventive Double Mastectomies
For women who are considering prophylactic bilateral mastectomies, “I strongly encourage genetic testing, Todd M. Tuttle, MD, MS, said in an interview with The ASCO Post about the increased interest in preventive double mastectomy following Angelina Jolie’s disclosure that she had the procedure to...
Angelina Jolie's Disclosure of Prophylactic Bilateral Mastectomy: A Positive Example for Women with BRCA Mutations?
Angelina Jolie, in a New York Times article entitled “My Medical Choice,”1 disclosed that having a BRCA1 mutation and an estimated 87% risk of breast cancer, “I decided to be proactive and minimize the risk as much I could. I made a decision to have a preventive double mastectomy.” She was writing...
New Susceptibility Variants for Childhood ALL in Ethnically Diverse Populations
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and the incidence of the disease varies by ethnicity. Available evidence indicates an inherited predisposition to ALL, but the genetic basis of ALL susceptibility in diverse ancestry has not been examined in detail. Xu and...
Epigenome-wide Study of DNA Methylation in Breast Cancer Using Prospectively Collected Samples
Available data suggest that DNA methylation in blood is a potential epigenetic marker of cancer risk, but this has not been evaluated on a genome-wide scale in prospective studies of breast cancer. Xu and colleagues measured DNA methylation at 27,578 CpG sites (ie, DNA regions where cytosine and...
Living Without Fear
Even before I had a colonoscopy to determine the cause of abdominal pains I had been having, I instinctively knew that the news wouldn’t be good. A colonoscopy and subsequent pathology report confirmed stage IIIC colorectal cancer. Because I was just 47 years old at the time of my diagnosis and had ...
Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by...
Partnership Seeks to Accelerate Development of Innovative Therapies
The Leukemia & Lymphoma Society (LLS) recently joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This Blood Cancer Research Partnership (BCRP) will...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
How to Recognize and Manage Hand-Foot Syndrome Due to Capecitabine or Doxorubicin
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that...
Dabrafenib for Unresectable or Metastatic Melanoma with BRAF V600E Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, dabrafenib (Tafinlar) was approved for ...
Improving Treatment and Care for Patients with Primary Brain Cancers
Despite advances in neuroimaging, the development of focused radiation therapy, and more effective chemotherapy, life expectancy for patients with primary malignant tumors of the brain and spinal cord remains stubbornly low at between 15 and 18 months. However, there are significant advances on the ...
Treating Both the Physical and Psychological Symptoms of Cancer
A growing number of people with cancer are being treated on an outpatient basis. At the Herbert Irving Comprehensive Cancer Center of New York-Presbyterian Hospital/Columbia University Medical Center in New York, to ensure that the psychosocial and psychiatric needs of these patients were being...
SIDEBAR: New Insights into Treatment for Two Types of Leukemia
The combination of functional and genomic screens has allowed us to accelerate the identification of oncogenes, as well as drug sensitivity that corresponds with those oncogenes. In the present study, we found that CSF3R mutations define chronic neutrophilic leukemia and atypical chronic myeloid...
Identification of Oncogenic Mutations in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Among the hematologic cancers for which molecular causes remain unclear are chronic neutrophilic leukemia and atypical (BCR-ABL1–negative) chronic myeloid leukemia. Both disorders currently are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic factors...
Similar Short-term Outcomes with Laparoscopic vs Open Surgery for Rectal Cancer
As recently reported in Lancet Oncology by Martijn H.G.M. van der Pas, MD, of VU University Medical Center, Amsterdam, and colleagues, the phase III COLOR II trial has shown that laparoscopic surgery can produce similar safety outcomes, resection margins, and completeness of resection compared with ...
Journal of Clinical Oncology Fosters the Development of Early-career Researchers through Support of Conquer Cancer Foundation Young Investigator Awards
The Conquer Cancer Foundation of the American Society of Clinical Oncology is dedicated to funding breakthrough research and sharing cutting-edge knowledge, and the Journal of Clinical Oncology (JCO) shares this commitment: It is ranked as the most widely read oncology journal worldwide, with a...
In Memoriam: ASCO Remembers Founding Member Jane Cooke Wright, MD
Earlier this year, ASCO and the oncology community at large lost a true pioneer, mentor, and renowned researcher. It is with great sadness that we mark the passing of Jane Cooke Wright, MD, one of seven founding members of ASCO—the only woman among the founders—and the Society’s first...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
National Institutes of Health Issues Projected Impact of Sequestration on Programs
Earlier this month, the National Institutes of Health (NIH) released its updated projections of reductions in programs due to the deficit-budget mechanism known as sequestration, which took effect on March 1, 2013. The sequestration law requires NIH to cut 5%, or $1.55 billion, of its fiscal year...
Study Shows High Concordance of Recurrent Somatic Alterations in Primary and Matched Metastatic NSCLC
In a study reported in Journal of Clinical Oncology, Stéphane Vignot, MD, of Institut National de la Santé et de la Recherche Medicale (INSERM) Unit 981, Paris, and Gustave Roussy Institute, Villejuif, France, and colleagues used next-generation sequencing to identify somatic alterations in...
KRAS Status Not Associated with Survival in Pooled Adjuvant Therapy Trials in Early-stage Lung Cancer
KRAS mutations have been reported in approximately 30% of lung adenocarcinomas. They occur most frequently in codons 12 and 13 in non–small cell lung cancer (NSCLC), and are most common in cancer in smokers and in nonsquamous NSCLC. Some data suggest that KRAS mutation is associated with poorer...
FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer
The U.S. Food and Drug Administration (FDA) recently approved two new drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), for patients with advanced or unresectable melanoma. Dabrafenib, a BRAF inhibitor, is approved to treat patients with melanoma whose tumors express the BRAF V600E gene...
Radiation-sparing Dose-adjusted EPOCH-Rituximab for Primary Mediastinal B-cell Lymphoma
Tumor control is frequently not achieved with standard immunochemotherapy in patients with primary mediastinal B-cell lymphoma, requiring consolidation with mediastinal radiotherapy. However, radiotherapy is associated with serious late adverse effects and is still associated with disease...
Expert Point of View: Carol Aghajanian, MD
Commenting on these results, Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, said, “There is currently no standard of care for maintenance therapy. Evidence continues to mount that targeting angiogenesis is important in...
Pazopanib Maintenance Therapy Extends Progression‑free Survival in Patients with Ovarian Cancer
Maintenance therapy with the targeted therapy pazopanib (Votrient) extended progression-free survival in women with ovarian cancer who were disease-free following initial treatment with surgery and chemotherapy, according to results of a phase III trial presented at the 49th Annual Meeting of...
FDA Approves New Silicone Gel-filled Breast Implant
The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 women...
Expert Point of View: Ann Partridge, MD
This study showed that 10 years of adjuvant tamoxifen reduced the risk of late recurrence in hormone receptor-positive breast cancer, which is a major problem. The study also showed that ‘patience is a virtue’,” stated formal discussant Ann Partridge, MD, Director of the Adult Survivorship Program...
